Publication

Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).

Journal Paper/Review - Jun 25, 2023

Units
PubMed
Doi
Contact

Citation
Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen D, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz C, Maggi N, Saccilotto R, Heidinger M, Müller A, Tampaki E, Bjelic-Radisic V, Sávolt Á, Smanykó V, Hagen D, Müller D, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kümmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr P, Gabriel N, Maráz R, Sarlos D, Dedes K, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer C, Montagna G, Reitsamer R, Winkler J, Lam G, Fehr M, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber W. Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). Breast Cancer Res Treat 2023; 201:215-225.
Type
Journal Paper/Review (English)
Journal
Breast Cancer Res Treat 2023; 201
Publication Date
Jun 25, 2023
Issn Electronic
1573-7217
Pages
215-225
Brief description/objective

The aim of this study was to evaluate clinical practice heterogeneity in use of neoadjuvant systemic therapy (NST) for patients with clinically node-positive breast cancer in Europe.